- Home
- MU vs ABBV Comparison
MU vs ABBV Comparison
Compare MU & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MU | ABBV |
|---|---|---|
| Founded | 1978 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 444.2B | 400.9B |
| IPO Year | 1994 | 2012 |
Fundamental Metrics
Financial Performance| Metric | MU | ABBV |
|---|---|---|
| Price | $388.84 | $227.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 30 | 19 |
| Target Price | ★ $348.89 | $247.06 |
| AVG Volume (30 Days) | ★ 25.3M | 5.7M |
| Earning Date | 03-17-2026 | 01-01-0001 |
| Dividend Yield | 0.12% | ★ 3.01% |
| EPS Growth | ★ 984.29 | N/A |
| EPS | ★ 4.60 | 2.36 |
| Revenue | $30,391,000,000.00 | ★ $61,160,000,000.00 |
| Revenue This Year | $112.37 | $11.90 |
| Revenue Next Year | $30.09 | $8.24 |
| P/E Ratio | ★ $80.97 | $97.66 |
| Revenue Growth | ★ 49.55 | 8.57 |
| 52 Week Low | $61.54 | $164.39 |
| 52 Week High | $455.50 | $244.81 |
Technical Indicators
Market Signals| Indicator | MU | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 47.87 | 49.40 |
| Support Level | $363.90 | $220.11 |
| Resistance Level | $443.72 | $231.00 |
| Average True Range (ATR) | 20.34 | 5.33 |
| MACD | -6.81 | -0.00 |
| Stochastic Oscillator | 29.55 | 37.05 |
Price Performance
Historical ComparisonAbout MU Micron Technology Inc.
Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips. Its primary revenue stream comes from dynamic random access memory, or DRAM, and it also has minority exposure to not-and or NAND, flash chips. Micron serves a global customer base, selling chips into data centers, mobile phones, consumer electronics, and industrial and automotive applications. The firm is vertically integrated.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.